enVVeno Medical (NVNO) news
Recent news
Enveno Medical: May offer and sell securities for up to $100 mln - SEC filing
EnVVeno Medical Corporation (NASDAQ: NVNO) has filed with the U.S. Securities and Exchange Commission (SEC) to offer and sell up to $100 million in securities, including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, debt securities, and units,…
AInvest Wire · Aug 21, 2026Envvivo Medical Corp: Tavve pivotal study expected to begin enrolling patients during the second half of this year
enVVeno Medical Corporation (NASDAQ:NVNO) has announced that it expects to begin enrolling patients in the TAVVE (Transcatheter Anti-reflux Venous Valve Endoprosthesis) pivotal study during the second half of 2026. The TAVVE trial is intended to evaluate enVVe, the company’s non-surgical…
AInvest Wire · Jul 31, 2026Envveno Medical Corp: Company enters the second half of 2026 with tailwinds from an FDA IDE approval
enVVeno Medical Corporation (NASDAQ:NVNO) is entering the second half of 2026 with a key regulatory milestone under its belt, following the U.S. Food and Drug Administration’s (FDA) Investigational Device Exemption (IDE) approval for its TAVVE U.S. Pivotal Study. This marks the first-ever FDA IDE…
AInvest Wire · Jul 31, 2026Envveno Medical: net loss Q2 2026 was $3.6 million, or $5.37 per basic and diluted share
AInvest Wire · Jul 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.